Quince Therapeutics, Inc. (QNCX) News
Track canonical SquawkNews coverage tagged to QNCX, Quince Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
QNCX - Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
QNCX - Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
NEWS | Sep 17, 2026, 12:00 PM UTC
L
Quince Therapeutics' Charles Ryan to Depart; Receives $1.014M Severance
Quince Therapeutics' President Charles Ryan departed effective September 8, 2026, under a Separation Agreement providing a $1,014,489.04 lump-sum severance payment.Original SEC Filing: Quince Therapeutics, Inc. [ QNCX ]
REGULATION | Sep 14, 2026, 08:46 PM UTC
L
QNCX: LAM-001 shows promise as an inhaled mTOR inhibitor for multiple pulmonary diseases, with pivotal data ahead
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, t
EQUITY | Sep 09, 2026, 08:12 PM UTC
L
QNCX: LAM-001 shows promise as a once-daily inhaled therapy for multiple high-need pulmonary diseases
LAM-001, a once-daily inhaled rapamycin, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with key data readouts expected in 2027 and 2028. Early results show strong pulmonary delivery, low systemic exposu
EQUITY | Sep 09, 2026, 07:43 PM UTC
M
Quince Therapeutics gets Nasdaq notice over equity shortfall
Nasdaq notified Quince Therapeutics it failed Listing Rule 5450(b)(1)(A) after stockholders’ equity of ($35.3M), below the $10M minimum. Shares continue on Nasdaq Global Select Market under QNCX; company has until Octobe
EQUITY | Sep 04, 2026, 12:34 PM UTC
L
Quince Therapeutics to participate in September 2026 investor conferences
Quince Therapeutics said senior management will participate in September 2026 investor conferences, according to the company’s announcement.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
QNCX - Quince Therapeutics to Participate in September 2026 Investor Conferences
QNCX - Quince Therapeutics to Participate in September 2026 Investor Conferences
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Quince Therapeutics president Charles Ryan to depart Sept 8, 2026
Charles Ryan will depart as president on Sept 8, 2026.
EQUITY | Aug 27, 2026, 08:35 PM UTC
L
Craig-Hallum initiates QNCX at Buy, sets $68.00 target
Craig-Hallum initiates coverage of QNCX with a Buy rating and a $68.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
L
Quince Therapeutics reports Q2 2026 financial results update
Quince Therapeutics (QNCX) reports Second Quarter 2026 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
SEC Filings: Multiple Companies
Multiple companies file with SEC
EQUITY | Aug 03, 2026, 09:28 AM UTC
L
QNCX Initiated Outperform and $82 PT @ OPCO
QNCX Initiated Outperform and $82 PT @ OPCO
EQUITY | Jul 29, 2026, 12:52 PM UTC
L
QNCX Initiated Outperform W/$82.00 PT at Oppenheimer
QNCX Initiated Outperform W/$82.00 PT at Oppenheimer
EQUITY | Jul 29, 2026, 11:59 AM UTC
H
Analysts Initiate Buys
Analysts initiate buy ratings
EQUITY | Jul 29, 2026, 11:15 AM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with OUTPERFORM, BUY, and EQUAL WEIGHT ratings
EQUITY | Jun 24, 2026, 10:54 AM UTC